Femme Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To determine the benefit of exemestane plus enzalutamide versus exemestane plus placebo as assessed by progression free survival (PFS) in patients with advanced breast cancer that is estrogen and/or progesterone receptor positive and human epidermal growth factor receptor 2 (HER2) normal and in the subset of patients with a genomic signature of differential gene expression based on RNA sequencing (Dx).
Critère d'inclusion
- Breast Cancer